These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20305756)

  • 1. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study.
    Carr BI; Pancoska P; Branch RA
    Hepatol Int; 2009 Dec; 4(1):396-405. PubMed ID: 20305756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study.
    Carr BI; Buch SC; Kondragunta V; Pancoska P; Branch RA
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1259-66. PubMed ID: 18699979
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
    J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.
    Carr BI; Guerra V
    Dig Dis Sci; 2016 Mar; 61(3):937-47. PubMed ID: 26576554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization.
    Dvorchik I; Carr BI
    Cancer Detect Prev; 2007; 31(2):154-60. PubMed ID: 17416468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance among aggressiveness characteristics of hepatocellular carcinoma: Portal vein thrombosis and multifocality, related to tumor size, but not to serum alpha-fetoprotein level.
    Carr BI; Guerra V; Ince V; Isik B; Yilmaz S
    Liver Res; 2023 Sep; 7(3):256-262. PubMed ID: 37854945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus Kinase-2 Mutation Associated Portal Vein Thrombosis Complicating Liver Cirrhosis and Hepatocellular Carcinoma.
    Rabie H; Othman W; Elsabaawy DM; Elshemy EE; Abdelmageed N; Khalaf FA; Bedair HM
    Asian Pac J Cancer Prev; 2021 Jan; 22(1):267-275. PubMed ID: 33507708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCC in older patients.
    Carr BI; Pancoska P; Branch RA
    Dig Dis Sci; 2010 Dec; 55(12):3584-90. PubMed ID: 20238246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients.
    Akkiz H; Carr BI; Yalçın K K; Guerra V; Kuran S; Altıntaş E; Üsküdar O; Karaoğullarından Ü; Özakyol A; Tokmak S; Yücesoy M; Bahçeci Hİ; Ülkü A; Akçam T; Yalçın Polat K; Ekinci N; Şimşek H; Örmeci N; Sonsuz A; Demir M; Kılıç M; Uygun A; Ballı T; Demir A; Arslan B; Doran F
    Oncology; 2018; 94(2):116-124. PubMed ID: 29207378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Portal Vein Thrombosis in Unresectable Hcc Cases: a Single Center Study of Prognostic Factors and Management in 140 Patients.
    Abdelmaksoud AH; Mandooh S; Nabeel MM; Elbaz TM; Shousha HI; Monier A; Elattar IA; Abdelaziz AO
    Asian Pac J Cancer Prev; 2017 Jan; 18(1):183-188. PubMed ID: 28240515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low alpha-fetoprotein HCC and the role of GGTP.
    Carr BI; Guerra V; Giannini EG; Farinati F; Ciccarese F; Rapaccini GL; Di Marco M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F
    Int J Biol Markers; 2014 Dec; 29(4):e395-402. PubMed ID: 24832180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplant and non-transplant HCC patients at a single institution.
    Carr BI; Bag H; Ince V; Isik B; Baskiran A; Yilmaz S
    Hepatol Forum; 2024; 5(2):77-86. PubMed ID: 38487742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Tumor Indices in Relation to Increased Hepatocellular Carcinoma Size: Evidence for Tumor Evolution as a Function of Growth.
    Carr BI; Guerra V; Donghia R; Yilmaz S
    J Gastrointest Cancer; 2020 Dec; 51(4):1215-1219. PubMed ID: 33006073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.
    Salem R; Lewandowski R; Roberts C; Goin J; Thurston K; Abouljoud M; Courtney A
    J Vasc Interv Radiol; 2004 Apr; 15(4):335-45. PubMed ID: 15064336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macroscopic Portal Vein Thrombosis in HCC Patients.
    Akkiz H; Carr BI; Kuran S; Karaoğullarından Ü; Üsküdar O; Tokmak S; Arslan B; Doran F; Balli HT; Ülkü A; Akçam TA; Bahçeci Hİ; Polat KY; Örmeci N; Şimşek H; Sonsuz A; Demir A; Altıntaş E; Demir M; Yalçın K; Ekinci N; Harmancı Özakyol A; Yücesoy M; Uygun A; Guerra V; Delik A; Tokat Y; Yilmaz S; Bektaş A; Kılıç M
    Can J Gastroenterol Hepatol; 2018; 2018():3120185. PubMed ID: 30009156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes.
    Carr BI; Guerra V; Donghia R; Yilmaz S
    Ann Med Surg (Lond); 2021 Jun; 66():102458. PubMed ID: 34141428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Portal Vein Thrombosis Predicts Concomitant Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients.
    Khoury T; Massarwa M; Hazou W; Daher S; Hakimian D; Benson AA; Ashqar T; Mahamid M; Yaari S
    J Gastrointest Cancer; 2019 Dec; 50(4):759-762. PubMed ID: 30043228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-mode and contrast enhanced ultrasound guided biopsy of portal vein thrombosis. Value in the diagnosis of occult hepatocellular carcinoma in liver cirrhosis.
    Sparchez Z; Radu P; Zaharia T; Kacso G; Diaconu B; Grigorescu I; Badea R
    Med Ultrason; 2010 Dec; 12(4):286-94. PubMed ID: 21210013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
    Kulik LM; Carr BI; Mulcahy MF; Lewandowski RJ; Atassi B; Ryu RK; Sato KT; Benson A; Nemcek AA; Gates VL; Abecassis M; Omary RA; Salem R
    Hepatology; 2008 Jan; 47(1):71-81. PubMed ID: 18027884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.